|
1
|
Chaudhary S, Manuja N, Ravishankar CT,
Sinha A, Vijayran M and Singh M: Oral melanotic neuroectodermal
tumor of infancy. J Indian Soc Pedod Prev Dent. 32:71–73. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andrade NN, Mathai PC, Sahu V, Aggarwal N
and Andrade T: Melanotic neuroectodermal tumour of infancy-A rare
entity. J Oral Biol Craniofac Res. 6:237–240. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neven J, Hulsbergen-van der Kaa C,
Groot-Loonen J, de Wilde PC and Merkx MA: Rucurrent melanotic
neuroectodermal tumor of infancy: A proposal for treatment protocol
with surgery and adjuvant chemotherapy. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 106:493–496. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ubale P, Baldwa N and Gujjar P:
Anaesthetic management of a neuroectodermal tumor of infancy: A
rare case report. Anaesth Essays Res. 11:251–253. 2017. View Article : Google Scholar
|
|
5
|
Łyskawa W: Chemiotherapy in the
neoplasmatic diseases treatment and its neurotoxicity. Anestezjol i
Ratow. 3:80–87. 2009.
|
|
6
|
Karasawa T and Steyger PS: An integrated
view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol
Lett. 237:219–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Işık A, Grassi A and Soran A: Positive
axilla in breast cancer; clinical practice in 2018. Eur J Breast
Health. 14:134–135. 2018.PubMed/NCBI
|
|
8
|
Isik A, Karavas E and Firat D: Spontaneous
milk fistula from an axillary accessory breast. Breast J.
25:1542019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olgun Y, Aktaş S, Altun Z, Kırkım G,
Kızmazoğlu DÇ, Erçetin AP, Demir B, İnce D, Mutafoğlu K, Demirağ B,
et al: Analysis of genetic and non genetic risk factors for
cisplatin ototoxicity in pediatric patients. Int J Pediatr
Otorhinolaryngol. 90:64–69. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Breglio AM, Rusheen AE, Shide ED,
Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L and
Cunningham LL: Cisplatin is retained in the cochlea indefinitely
following chemotherapy. Nat Commun. 8:16542017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Einarsson EJ, Petersen H, Wiebe T,
Fransson PA, Grenner J, Magnusson M and Moëll C: Long term hearing
degeneration after platinum-based chemotherapy in childhood. Int J
Audiol. 49:765–771. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dean JB, Hayashi SS, Albert CM, King AA,
Karzon R and Hayashi RJ: Hearing loss in pediatric oncology
patients receiving carboplatin-containing regimens. J Pediatr
Hematol Oncol. 30:130–134. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sheth S, Mukherjea D, Rybak LP and
Ramkumar V: Mechanisms of cisplatin-induced ototoxicity and
otoprotection. Front Cell Neurosci. 11:3382017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Clemens E, de Vries AC, Pluijm SF, Am
Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder
E, Bresters D, Versluys B, Kremer LC, et al: Determinants of
ototoxicity in 451 platinum-treated Dutch survivors of childhood
cancer: A DCOG late-effects study. Eur J Cancer. 69:77–85. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bertolini P, Lassalle M, Mercier G, Raquin
MA, Izzi G, Corradini N and Hartmann O: Platinum compound-related
ototoxicity in children: Long-term follow-up reveals continuous
worsening of hearing loss. J Pediatr Hematol Oncol. 26:649–655.
2004. View Article : Google Scholar
|
|
16
|
Bess FH, Dodd-Murphy J and Parker RA:
Children with minimal sensorineural hearing loss: Prevalence,
educational performance, and functional status. Ear Hear.
19:339–354. 1998. View Article : Google Scholar
|
|
17
|
Davis JM, Elfenbein J, Schum R and Bentler
RA: Effects of mild and moderate hearing impairments on language,
educational, and psychosocial behavior of children. J Speech Hear
Disord. 51:53–62. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sergi B, Ferraresi A, Troiani D, Paludetti
G and Fetoni AR: Cisplatin ototoxicity in the guinea pig:
Vestibular and cochlear damage. Hear Res. 182:56–64. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Clemens E, de Vries AC, Am
Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, Pluijm SF, van
Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, et al:
Hearing loss after platinum treatment is irreversible in noncranial
irradiated childhood cancer survivors. Pediatr Hematol Oncol.
34:120–129. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin CP, Liu JD, Chow JM, Liu CR and Liu
HE: Small-molecule c-Myc inhibitor, 10058-F4, inhibits
proliferation, downregulates human telomerase reverse transcriptase
and enhances chemosensitivity in human hepatocellular carcinoma
cells. Anticancer Drugs. 18:161–117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fetoni AR, Ruggiero A, Lucidi D, De Corso
E, Sergi B, Conti G and Paludetti G: Audiological monitoring in
children treated with platinum chemotherapy. Audiol Neurootol.
21:203–211. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Waissbluth S, Chuang A, Del Valle Á and
Cordova M: Long term platinum-induced ototoxicity in pediatric
patients. Int J Pediatr Otorhinolaryngol. 107:75–79. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kushner BH, Budnick A, Kramer K, Modak S
and Cheung NK: Ototoxicity from high-dose use of platinum compounds
in patients with neuroblastoma. Cancer. 107:417–422. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liberman PH, Goffi-Gomez MV, Schultz C,
Novaes PE and Lopes LF: Audiological profile of patients treated
for childhood cancer. Braz J Otorhinolaryngol. 82:623–629. 2016.
View Article : Google Scholar : PubMed/NCBI
|
